The National Hepatitis B Mapping Project
Conducted in partnership with ASHM, and funded by the Commonwealth Department of Health, the National Hepatitis B Mapping Project generates estimates of the number of Australians living with chronic hepatitis B at a national, state/territory, and local area level, and reports on uptake of diagnosis, monitoring and treatment for hepatitis B. These estimates, together with assessment of local priority populations affected by hepatitis B, allow policy makers, community agencies and clinicians to target appropriate responses to this chronic viral infection in their local area. For further details, see http://www.ashm.org.au/HBVmapping/
Blood-borne viruses and sexually transmissible infections surveillance and research program
Surveillance for hepatitis B indicators
3-year project, 1 July 2016 – 30 June 2019
A key aspect of Australia’s National Hepatitis B Strategy 2014-2017 is the identification of specific measurable aims and targets, including increasing the proportion of people living with chronic hepatitis B who have been diagnosed, increasing treatment uptake, and reducing the burden of attributable morbidity and mortality. Measuring progress towards these objectives will allow for identification of priority areas for improvement, and assessment of progress over time in order to shape the public health and policy response to hepatitis B. This project aims to develop disease burden estimation and mathematical modelling approaches to inform the surveillance, monitoring and evaluation of progress towards achieving the objectives of the Second National Hepatitis B Strategy 2014-2017.
Liver Cancer Prevention
Linking viral hepatitis diagnosis, treatment and outcomes
Through health record linkage, combining notifications of viral hepatitis diagnosis, liver cancer diagnoses, hospitalisations, and deaths, as well as records of services provided through the Medicare and Pharmaceutical Benefits programs, this project will develop an accurate picture of the burden of viral hepatitis in Victoria, and measure the impact of care and treatment at a population level as a cancer prevention strategy. By examining the current level of access to care, and measuring the effectiveness of treatment received in preventing liver cancer, this research will guide clinical and public health policy and help address the increasing burden of liver cancer in Australia.
Victorian Enhanced Viral Hepatitis Surveillance Project
On behalf of and in collaboration with the Department of Health and Human Services, the Enhanced Viral Hepatitis Surveillance Project aims to simplify the process of chronic hepatitis B and C notification in Victoria, to increase notification data completeness and improve and inform public health and policy responses. The project also aims to increase clinicians’ awareness and engagement regarding viral hepatitis, improving care and prevention access for those diagnosed, increase vaccine ordering and improving the ability to identify cases of chronic viral hepatitis with potential public health significance.
Associate Professor Benjamin Cowie
(03) 9342 9374 | [email protected]
- Director, WHO Collaborating Centre for Viral Hepatitis
- Immunology, Emerging Infections, Hepatitis
- Translational and Clinical Research, Education & Professional Development, Epidemiology, Global Health, Indigenous Health, Public Health
- The University of Melbourne, Victorian Infectious Diseases Reference Laboratory (VIDRL), Victorian Infectious Diseases Service (VIDS)
- Lab Group(s):
- Cowie Group
Associate Professor Benjamin Cowie is an infectious diseases physician and epidemiologist, with appointments in both the Epidemiology Unit at VIDRL and VIDS. In addition, Ben is a medical epidemiologist with Communicable Disease Epidemiology and Surveillance, Victorian Department of Health and Human Services, and is an Honorary Principal Fellow in the Department of Medicine at the University of Melbourne. He serves on a range of communicable disease, clinical and public health committees at state, national and international levels.